Publications by authors named "Isil Altintas"

Claim this Profile
A
A hexamerization-enhanced, Fc-silenced agonistic CD27 antibody amplifies T-cell effector functions as single agent and in combination with PD-1 blockade.
Işıl Altıntaş, Kristina B Nürmberger, Andrea Imle, Anna-Lena Krause, Marike M van Beuge

Sci Rep· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Epcoritamab monotherapy in patients with relapsed or refractory follicular lymphoma (EPCORE NHL-1): a phase 2 cohort of a single-arm, multicentre study.
Kim M Linton, Umberto Vitolo, Wojciech Jurczak, Pieternella J Lugtenburg, Emmanuel Gyan

Lancet Haematol· August 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
DuoBody-CD40x4-1BB induces dendritic-cell maturation and enhances T-cell activation through conditional CD40 and 4-1BB agonist activity.
Alexander Muik, Homer C Adams 3rd, Friederike Gieseke, Isil Altintas, Kristina B Schoedel

J Immunother Cancer· June 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Preclinical Characterization and Phase I Trial Results of a Bispecific Antibody Targeting PD-L1 and 4-1BB (GEN1046) in Patients with Advanced Refractory Solid Tumors.
Alexander Muik, Elena Garralda, Isil Altintas, Friederike Gieseke, Ravit Geva

Cancer Discov· May 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
An Fc-inert PD-L1×4-1BB bispecific antibody mediates potent anti-tumor immunity in mice by combining checkpoint inhibition and conditional 4-1BB co-stimulation.
Alexander Muik, Isil Altintas, Friederike Gieseke, Kristina B Schoedel, Saskia M Burm

Oncoimmunology· April 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
CD3-Bispecific Antibody Therapy Turns Solid Tumors into Inflammatory Sites but Does Not Install Protective Memory.
Hreinn Benonisson, Işıl Altıntaş, Marjolein Sluijter, Sandra Verploegen, Aran F Labrijn

Mol Cancer Ther· February 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficient Generation of Bispecific Murine Antibodies for Pre-Clinical Investigations in Syngeneic Rodent Models.
Aran F Labrijn, Joyce I Meesters, Matthew Bunce, Anthony A Armstrong, Sandeep Somani

Sci Rep· May 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Targeting hepatocyte growth factor receptor (Met) positive tumor cells using internalizing nanobody-decorated albumin nanoparticles.
Raimond Heukers, Isil Altintas, Smiriti Raghoenath, Erica De Zan, Richard Pepermans

Biomaterials· January 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Inhibition of tumor growth by targeted anti-EGFR/IGF-1R nanobullets depends on efficient blocking of cell survival pathways.
Roy van der Meel, Sabrina Oliveira, Isil Altintas, Raimond Heukers, Ebel H E Pieters

Mol Pharm· October 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Nanobody-albumin nanoparticles (NANAPs) for the delivery of a multikinase inhibitor 17864 to EGFR overexpressing tumor cells.
Isil Altintas, Raimond Heukers, Roy van der Meel, Marie Lacombe, Maryam Amidi

J Control Release· January 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Glucocorticoid-loaded core-cross-linked polymeric micelles with tailorable release kinetics for targeted therapy of rheumatoid arthritis.
Bart J Crielaard, Cristianne J F Rijcken, Lingdong Quan, Steffen van der Wal, Isil Altintas

Angew Chem Int Ed Engl· July 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Tumor-targeted Nanobullets: Anti-EGFR nanobody-liposomes loaded with anti-IGF-1R kinase inhibitor for cancer treatment.
Roy van der Meel, Sabrina Oliveira, Isil Altintas, Rob Haselberg, Joris van der Veeken

J Control Release· April 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Targeting epidermal growth factor receptor in tumors: from conventional monoclonal antibodies via heavy chain-only antibodies to nanobodies.
Isil Altintas, Robbert Jan Kok, Raymond M Schiffelers

Eur J Pharm Sci· March 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis